Effects of Precuneus Repetitive Transcranial Magnetic Stimulation (rTMS) on Self-Referential Processing and Default Mode Network Functional Connectivity in Early Phase Psychosis
M
Michael Francis, MD
Primary Investigator
Overview
The purpose of this study is to determine if the study treatment, repetitive transcranial magnetic
stimulation (rTMS), helps improve symptoms of your illness and adjusts communication between
related areas of the brain. rTMS is a non-invasive technique that applies a magnetic field over the scalp
to cause activation within the brain.
stimulation (rTMS), helps improve symptoms of your illness and adjusts communication between
related areas of the brain. rTMS is a non-invasive technique that applies a magnetic field over the scalp
to cause activation within the brain.
Eligibility
You may be eligible for this study if you meet the following criteria:
-
Conditions:
Schizophrenia, schizoaffective disorder
-
Age: Between 18 Years - 45 Years
-
Gender: All
Inclusion Criteria
1. Between 18 and 45 years of age
2. Within 10 years of illness onset as defined by entry into treatment for psychotic symptoms
3. Able to give informed consent
4. Willing and able to adhere to the study schedule
5. Structured Clinical Interview for DSM-5 (SCID-5)67 diagnosis of schizophrenia or schizoaffective disorder
6. Clinical stability as defined by your care provider.
Exclusion Criteria
1. Lifetime history of a seizure, excluding febrile seizures and those induced by substance withdrawal
2. First degree relative (that is, biological father, mother, brother, sister, or child) with idiopathic epilepsy or other seizure disorder
3. History of significant neurological illness (including stroke, CNS infection with persistent neurologic deficit, or other event deemed significant by PI)
4. History of head trauma as defined by a loss of consciousness or a post-concussive syndrome
5. Pregnant or breast feeding
6. Known IQ < 70 based
7. Current acute, serious, or unstable medical conditions, including, but not limited to: inadequately controlled diabetes, asthma, COPD, severe hypertriglyceridemia, recent cerebrovascular accidents, acute systemic infection or immunologic disease, unstable cardiovascular disorders, malnutrition, or hepatic, renal gastroenterological, respiratory, endocrine, neurologic, hematologic, or infectious diseases based on medical history or physical examination
8. Metallic objects planted in or near the head, including implanted pacemaker, medication pump, vagal stimulator, deep brain stimulator, TENS unit, ventriculoperitoneal shunt, or cochlear implants
9. Contraindications to MRI or otherwise unable to tolerate MRI procedures
10. History of electroconvulsive therapy
11. Taking clozapine
12. Participated in a clinical trial with any pharmacological treatment intervention for which they received study-related medication in the 4 weeks prior to randomization
13. Considered a high risk for suicidal acts – active suicidal ideation as determined by clinical interview OR any suicide attempt in 90 days prior to screening
14. Current DSM-5 diagnosis of substance use disorder (excluding nicotine or caffeine)
15. Require concomitant treatment with prohibited medication
1. Between 18 and 45 years of age
2. Within 10 years of illness onset as defined by entry into treatment for psychotic symptoms
3. Able to give informed consent
4. Willing and able to adhere to the study schedule
5. Structured Clinical Interview for DSM-5 (SCID-5)67 diagnosis of schizophrenia or schizoaffective disorder
6. Clinical stability as defined by your care provider.
Exclusion Criteria
1. Lifetime history of a seizure, excluding febrile seizures and those induced by substance withdrawal
2. First degree relative (that is, biological father, mother, brother, sister, or child) with idiopathic epilepsy or other seizure disorder
3. History of significant neurological illness (including stroke, CNS infection with persistent neurologic deficit, or other event deemed significant by PI)
4. History of head trauma as defined by a loss of consciousness or a post-concussive syndrome
5. Pregnant or breast feeding
6. Known IQ < 70 based
7. Current acute, serious, or unstable medical conditions, including, but not limited to: inadequately controlled diabetes, asthma, COPD, severe hypertriglyceridemia, recent cerebrovascular accidents, acute systemic infection or immunologic disease, unstable cardiovascular disorders, malnutrition, or hepatic, renal gastroenterological, respiratory, endocrine, neurologic, hematologic, or infectious diseases based on medical history or physical examination
8. Metallic objects planted in or near the head, including implanted pacemaker, medication pump, vagal stimulator, deep brain stimulator, TENS unit, ventriculoperitoneal shunt, or cochlear implants
9. Contraindications to MRI or otherwise unable to tolerate MRI procedures
10. History of electroconvulsive therapy
11. Taking clozapine
12. Participated in a clinical trial with any pharmacological treatment intervention for which they received study-related medication in the 4 weeks prior to randomization
13. Considered a high risk for suicidal acts – active suicidal ideation as determined by clinical interview OR any suicide attempt in 90 days prior to screening
14. Current DSM-5 diagnosis of substance use disorder (excluding nicotine or caffeine)
15. Require concomitant treatment with prohibited medication
Updated on
17 Apr 2024.
Study ID: 1904511224
